Vancouver, British Columbia – TheNewswire – April 27, 2020 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (Frankfurt:0JJ); (OTC:BLRZF) (the “Corporation” or “Blackhawk”), is pleased to announce that it has formed a strategic advisory board to advise and consult with the board of directors and senior management. The Corporation has appointed Niv Dagan as the initial member of the advisory board. Mr. Dagan will be a valuable addition to the team and will greatly assist Blackhawk in realizing its vision and investment goals. To further advance sales of our test kits in North America and Europe, Blackhawk will look to bolster this board with medical and scientific advisors.
Prior to founding Peak in 2013, Niv headed up HC Securities; spent three years growing its capital markets division and worked on the wholesale desk at Macquarie Bank, servicing a wide range of institutional, intermediary and offshore clients. Niv takes an active approach in managing client funds and is passionate about backing strong management teams that deliver shareholder value. Niv’s focus is identifying great companies that are traditionally not offered to retail and institutional investors and sees a large opportunity in assisting Australian companies expand their presence in the North American markets.
Frederick Pels, CEO of Blackhawk states: “We are pleased to welcome Niv to our team. His knowledge and experience are a valuable addition. He brings a wealth of global contacts that we will surely leverage as we look to expand our operations globally. His support and guidance will be a relied upon tool we will use to further Blackhawk’s ability to distribute the Innovita COVID-19 test kits around the globe. On behalf of our whole team, we look forward to working with Mr. Dagan and updating our shareholders with our progress over the coming weeks.”
“I am excited to join Blackhawk as a strategic advisor and work closely with Fred and the team” says Niv Dagan. “The landscape is shaping rapidly and we have a huge opportunity here to make a paradigm difference.”
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the fulfillment of an order for the delivery of COVID-19 testing kits, and anticipated future orders. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.